RESUMO
In 15-20% of cases, Graves' disease (GD) shifts to Hashimoto's thyroiditis (HT), while the shift from HT to GD is rare. We present a case of a patient in whom HT shifted to GD, along with a literature review. A 50-year-old woman with myxedema was diagnosed with Hashimoto's disease due to hypothyroidism and the presence of antibodies against thyroid peroxidase (TPOAb) and thyroglobulin (TgAb); she also had thyroid stimulating antibodies (TSAb) without any signs of GD. Although thyroid hormone replacement therapy improved her thyroid function, 2 months later, hyperthyroidism appeared and did not improve after discontinuation of the replacement therapy. The patient was diagnosed with GD, which improved with antithyroid agent administration. To date, only 50 cases regarding conversion from HT to GD have been reported. The median age is 44 years (range, 23-82 years), and the median time of conversion is 7 years (range, 0.1-27 years). The male-to-female ratio of HT conversion to GD is 1:9, closer to that of regular GD (1:10) than that of general HT (1:18). All patients received thyroid hormone replacement therapy for hypothyroidism due to HT. Continuous evaluation of TSAb levels is recommended in HT, particularly in cases of TSAb-positive and those under replacement, since it may help predict conversion to GD. Evaluating the clinical characteristics of patients with HT preceding GD is crucial to ensure appropriate treatment and reduce the risk of adverse events.
Assuntos
Doença de Graves , Doença de Hashimoto , Hipertireoidismo , Hipotireoidismo , Tireoidite Autoimune , Humanos , Masculino , Feminino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Doença de Hashimoto/complicações , Doença de Hashimoto/diagnóstico , Doença de Hashimoto/tratamento farmacológico , Doença de Graves/complicações , Doença de Graves/tratamento farmacológicoRESUMO
Focal segmental glomerulosclerosis (FSGS) is a leading cause of end-stage renal disease in children and adults. Genetic factors significantly contribute to early-onset FSGS, but the etiologies of most adult cases remain unknown. Genetic studies of monogenic syndromic FSGS exhibiting extra-renal manifestations have uncovered an unexpected biological role for genes in the development of both podocytes and other cellular lineages. To help define these roles, we studied two unrelated families with FSGS associated with Duane Retraction Syndrome, characterized by impaired horizontal eye movement due to cranial nerve malformation. All four affected individuals developed FSGS and Duane Retraction Syndrome in their first to second decade of life, manifested as restricted abduction together with globe retraction and narrowed palpebral fissure on attempted adduction. Hypoplasia of the abducens nerves and hearing impairment occurred in severely affected individuals. Genetic analyses revealed that affected individuals harbor a rare heterozygous substitution (p.Leu239Pro) in MAFB, a leucine zipper transcription factor. Luciferase assays with cultured monocytes indicated that the substitution significantly reduced transactivation of the F4/80 promoter, the known MAFB recognition element. Additionally, immunohistochemistry indicated reduced MAFB expression in the podocytes of patients. Structural modeling suggested that the p.Leu239Pro substitution in the DNA-binding domain possibly interferes with the stability of the adjacent zinc finger. Lastly, podocytes in neonatal mice with p.Leu239Pro displayed impaired differentiation. Thus, MAFB mutations impair development and/or maintenance of podocytes, abducens neurons and the inner ear. The interactions between MAFB and regulatory elements in these developing organs are likely highly specific based on spatiotemporal requirements.
Assuntos
Síndrome da Retração Ocular/etiologia , Glomerulosclerose Segmentar e Focal/genética , Falência Renal Crônica/etiologia , Fator de Transcrição MafB/genética , Adolescente , Adulto , Idade de Início , Substituição de Aminoácidos , Animais , Criança , Síndrome da Retração Ocular/patologia , Feminino , Testes Genéticos , Glomerulosclerose Segmentar e Focal/complicações , Glomerulosclerose Segmentar e Focal/patologia , Heterozigoto , Humanos , Falência Renal Crônica/patologia , Masculino , Camundongos , Mutação , Podócitos/patologia , Domínios Proteicos/genética , Homologia de Sequência de Aminoácidos , Adulto JovemRESUMO
BACKGROUND: Ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) is caused by tumours releasing ACTH. Ectopic ACTH-producing tumour regression is rarely induced using steroidogenesis inhibitors. We presented a case of EAS in which ACTH production by a lung tumour was reduced by metyrapone (MTP) and also reviewed previous cases of ectopic ACTH production suppressed via steroidogenesis inhibition. CASE PRESENTATION: A 71-year-old female with general fatigue, central obesity and impaired glucose tolerance was diagnosed with Cushing's syndrome due to elevated ACTH (192.9 pg/mL; normal range, 7.2-63.3 pg/mL), cortisol (73.1 µg/dL; 6.4-21.0 µg/dL) and 24-h urinary free cortisol (UFC) (6160 µg/day; 11.2-80.3 µg/day) levels. Chest computed tomography identified a solid 26.6 × 22.9 × 30.0 mm tumour with a cavity in the upper lobe of the left lung. There was no adrenal gland enlargement. Tumour markers were not significantly elevated; ACTH levels were not suppressed by 8-mg dexamethasone. A corticotropin-releasing hormone stimulation test revealed blunted ACTH response (basal ACTH, 204.6 pg/mL; highest ACTH level during the 120-min stimulation test, 214.0 pg/mL). She was diagnosed with EAS due to a lung lesion. MTP treatment was started to reduce cortisol production. ACTH levels and cortisol and UFC levels were normalised and the ACTH-producing lung tumour was ablated after MTP treatment. In several reported cases, plasma ACTH levels reduced during steroidogenesis inhibitor treatment for EAS. Among the 10 patients, three cases of pheochromocytoma, one of thymic carcinoid and one of islet cell carcinoma were reported. In four cases, the tumour was not detected. In our case, the pathology of the lung tumour was unknown because of lack of tumour cells in biopsy. The patients were treated with ketoconazole (KTZ) and/or MTP and exhibited ACTH and cortisol/UFC suppression, but tumour regression was observed only in our case. CONCLUSION: MTP and/or KTZ may reduce ACTH and cortisol production. The tumour spontaneously regressed after MTP treatment, indicating that MTP may reduce the tumour size without surgery. The mechanisms of therapeutic effects of steroidogenesis inhibitors and prognosis of spontaneous remission should be elucidated further via molecular biology studies.
Assuntos
Síndrome de ACTH Ectópico/complicações , Hormônio Adrenocorticotrópico/sangue , Hidrocortisona/sangue , Neoplasias Pulmonares/tratamento farmacológico , Metirapona/uso terapêutico , Idoso , Feminino , Humanos , Neoplasias Pulmonares/sangue , Neoplasias Pulmonares/etiologia , Prognóstico , Indução de RemissãoRESUMO
OBJECTIVES: Patients with an autism spectrum disorder (ASD) are prone to disruptive behaviors and aggression. Atypical antipsychotics are used to treat these difficult ASD conditions. Several psychotropic drugs have been linked to hypothyroidism. The clinical manifestation of hypothyroidism is indistinguishable from that of an antipsychotic's general adverse effect, which can lead to a delayed or missed diagnosis. Conversely, thyroid dysfunction can exhibit an impact on mood, anxiety, depression, and cognitive functions. CASE STUDY: We present a case of central hypothyroidism caused by long-term use of valproic acid (VPA) and adding quetiapine to risperidone. The current case had a history of hyperprolactinemia and subclinical hypothyroidism caused by risperidone and VPA, respectively, before the administration of quetiapine. CONCLUSION: This is the first report of quetiapine-induced central hypothyroidism in a patient with ASD, as determined by a thyrotropin-releasing hormone (TRH) loading test. TRH loading test may be useful in elucidating the pathogenesis of hypothyroidism in patients receiving quetiapine and VPA. Thyroid function monitoring in patients taking quetiapine and VPA may provide an opportunity to begin replacement therapy.
RESUMO
We studied histologic findings of age-related change in the posterior pituitary gland focusing specifically on abnormal deposition of tau protein. Posterior pituitary glands from a total of 201 patients with mean age of 72, range 15 to 100 years, were dissected at autopsy, and semiquantitative analysis of tau protein deposition in the posterior pituitaries was performed. We confirmed that tau protein deposition in the posterior pituitary appears histologically as either a 'thread-like' or 'dot' form. In double staining using an anti-neurofilament antibody and Gallyas-Braak staining, Gallyas-Braak-positive structures were located in the neurite. The grade and the frequency of tau protein deposition were increased in accord with aging. An interrelation was observed between tau protein deposition in the brain and that in the posterior pituitary. In tauopathy diseases, tau protein deposition in the posterior lobe is advanced compared to that in non-tauopathy diseases. The level of tau protein deposition in the hypothalamus was compared semi-quantitatively with that in the posterior pituitary, and the levels correlated well. We suggest that in the posterior pituitary of elderly people, high frequency of occurrence of deposition of abnormal tau protein in the neurites may cause dysfunction of the pituitary gland.
Assuntos
Envelhecimento/metabolismo , Neurônios/metabolismo , Neuro-Hipófise/metabolismo , Proteínas tau/metabolismo , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Envelhecimento/patologia , Encéfalo/metabolismo , Encéfalo/patologia , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Emaranhados Neurofibrilares/metabolismo , Emaranhados Neurofibrilares/patologia , Neurônios/patologia , Neuro-Hipófise/patologiaRESUMO
BACKGROUND AND AIMS: Direct measurement of arginine vasopressin (AVP) via immunoassays is not widely conducted, mainly because of technical constraints. Liquid chromatography-tandem mass spectrometry (LC/MS/MS) has been widely used as the gold standard in clinical chemistry. Here, we aimed to develop an MS-based assay to determine human plasma AVP and compare the results with those obtained using a conventional immunoassay. MATERIALS AND METHODS: We developed a protocol using triple quadrupole MS coupled with LC for the measurement of human plasma AVP. Analytical evaluations of the method were performed, and the results obtained using LC/MS/MS and radioimmunoassay (RIA) were compared. RESULTS: The lower limit of quantification (LLOQ) for plasma AVP obtained using LC/MS/MS and RIA were 0.2 and 0.4 pg/mL, respectively. Although there was a weak overall correlation between the results obtained using the two different methods, the RIA results did not agree with the LC/MS/MS results, particularly at low concentrations. CONCLUSIONS: AVP detection through RIA is not satisfactory compared with that using LC/MS/MS. Diagnostic values of direct AVP measurements must be evaluated based on the results obtained via sensitive and accurate MS-based methods rather than those obtained through RIA.
Assuntos
Arginina Vasopressina/sangue , Cromatografia Líquida de Alta Pressão/métodos , Espectrometria de Massas em Tandem/métodos , Feminino , Humanos , Limite de Detecção , MasculinoRESUMO
We evaluated the diagnostic accuracy of insulin-like growth factor-1 (IGF-1) for screening growth hormone deficiency (GHD) to determine the usefulness of IGF-1 as a screening test. Among 298 consecutive children who had short stature or decreased height velocity, we measured IGF-1 levels and performed growth hormone (GH) secretion test using clonidine, arginine, and, in cases with different results of the two tests, L-dopa. Patients with congenital abnormalities were excluded. GHD was defined as peak GH ≤ 6.0 ng/mL in the two tests. We identified 60 and 238 patients with and without GHD, respectively. The mean IGF-1 standard deviation (SD) was not significantly different between the GHD and non-GHD groups (p = 0.23). Receiver operating characteristic curve analysis demonstrated the best diagnostic accuracy at an IGF-1 cutoff of - 1.493 SD, with 0.685 sensitivity, 0.417 specificity, 0.25 positive and 0.823 negative predictive values, and 0.517 area under the curve. Correlation analysis revealed that none of the items of patients' characteristics increased the diagnostic power of IGF-1. IGF-1 level had poor diagnostic accuracy as a screening test for GHD. Therefore, IGF-1 should not be used alone for GHD screening. A predictive biomarker for GHD should be developed in the future.
Assuntos
Transtornos do Crescimento/sangue , Transtornos do Crescimento/diagnóstico , Hormônio do Crescimento Humano/deficiência , Fator de Crescimento Insulin-Like I/metabolismo , Algoritmos , Arginina/administração & dosagem , Biomarcadores/sangue , Estatura , Criança , Pré-Escolar , Clonidina/administração & dosagem , Estudos Transversais , Programas de Triagem Diagnóstica , Feminino , Humanos , Levodopa/administração & dosagem , Masculino , Valor Preditivo dos Testes , Estudos Prospectivos , Curva ROCRESUMO
Hypophosphatasia (HPP) is a rare skeletal disorder caused by loss-of-function mutations in Alkaline Phosphatase, Biomineralization associated (ALPL) gene that encodes tissue-nonspecific alkaline phosphatase. Odontohypophosphatasia (odonto-HPP), a mild form of HPP, is characterized only by oral manifestations including premature exfoliation of deciduous teeth. Enzyme replacement therapy (ERT) is effective in severe HPP cases; however, information about its efficacy for odonto-HPP is limited. A 2-yr-old girl was referred to our hospital for mobility of her deciduous teeth with low serum alkaline phosphatase (ALP) level of 253 U/L (reference range: 410-1,150 U/L) and high urine phosphoethanolamine level of 1,419.9 µmol/g·Cre (7-70 µmol/g·Cre). She had no history of bone fractures; however, several members of her family had low serum ALP levels with a history of pathological fractures. She had a novel heterozygous missense mutation (c.1183A>T, p.Ile395Phe) in ALPL, and therefore, was diagnosed with odonto-HPP. After she was provided ERT to prevent premature exfoliation, no tooth mobility was observed. However, two deciduous teeth exfoliated two months after starting ERT, which was possibly triggered by a bout of common cold. Starting ERT following tooth mobility might be relatively late. Previous studies on experimental mice showed that starting ERT at birth may be effective in preventing premature exfoliation of deciduous teeth.
RESUMO
Juvenile hemochromatosis (JH), type 2A hemochromatosis, is a rare autosomal recessive disorder of systemic iron overload due to homozygous mutations of HJV (HFE2), which encodes hemojuvelin, an essential regulator of the hepcidin expression, causing liver fibrosis, diabetes, and heart failure before 30 years of age, often with fatal outcomes. We report two Japanese sisters of 37 and 52 years of age, with JH, who showed the same homozygous HJV I281T mutation and hepcidin deficiency and who both responded well to phlebotomy on an outpatient basis. When all reported cases of JH with homozygous HJV mutations in the relevant literature were reviewed, we found-for the first time-that JH developed in females and males at a ratio of 3:2, with no age difference in the two groups. Furthermore, we found that the age of onset of JH may depend on the types of HJV mutations. In comparison to patients with the most common G320V/G320V mutation, JH developed earlier in patients with L101P/L101P or R385X/R385X mutations and later in patients with I281T/I281T mutations.
RESUMO
Adefovir dipivoxil (ADV) is effective for hepatitis B virus (HBV) infection; however, ADV may provoke renal injury resulting in osteomalacia, and this side effect is seldom recognized until bone fractures emerge. We herein present a 66-year-old woman with HBV infection who received ADV for 6 years. Although she exhibited no sign of bone fractures, her urinary ß-2 microglobulin (ß2MG) level increased to 83,837 µg/L and scintigraphy revealed minimal fractures of the third rib. ADV was subsequently reduced and her urinary ß2MG rapidly fell to 3,637 µg/L. Conversely, her urinary N-acetyl-ß-D-glucosaminidase, and serum phosphate, alkaline phosphatase levels did not respond.
Assuntos
Adenina/análogos & derivados , Antivirais/uso terapêutico , Hepatite B Crônica/diagnóstico , Hepatite B Crônica/tratamento farmacológico , Organofosfonatos/efeitos adversos , Osteomalacia/induzido quimicamente , Osteomalacia/terapia , Microglobulina beta-2/urina , Adenina/efeitos adversos , Idoso , Feminino , Humanos , Japão , Osteomalacia/diagnósticoRESUMO
A 49-year-old man with syringomyelia and a Type I Arnold-Chiari malformation (Chiari-I) was diagnosed with growth hormone insensitivity syndrome (GHIS). He was short in stature, had high circulating levels of GH, and low circulating levels of insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3). His GH responses to the administration of growth hormone-releasing hormone (GHRH) and L-DOPA were normal, but his levels of IGF-I and IGFBP-3 did not increase after the administration of exogenous GH. Direct genomic DNA sequencing revealed neither a mutation nor deletion in this patient's GH receptor (GHR) gene, though one polymorphism was detected, indicating that his GHR gene was normal. This is the first reported case of an association of GHIS with syringomyelia and Chiari-I malformation.
Assuntos
Malformação de Arnold-Chiari/sangue , Hormônio do Crescimento Humano/sangue , Siringomielia/sangue , Hormônio Liberador de Hormônio do Crescimento/metabolismo , Humanos , Proteína 3 de Ligação a Fator de Crescimento Semelhante à Insulina/sangue , Fator de Crescimento Insulin-Like I/metabolismo , Levodopa , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Hormônios Hipofisários/sangue , Análise de Sequência de DNAAssuntos
Linfocitose/tratamento farmacológico , Metilprednisolona/administração & dosagem , Doenças da Hipófise/tratamento farmacológico , Adeno-Hipófise/patologia , Feminino , Humanos , Hipopituitarismo/tratamento farmacológico , Hipopituitarismo/patologia , Linfocitose/patologia , Imageamento por Ressonância Magnética , Masculino , Doenças da Hipófise/patologia , Testes de Função Hipofisária , Prognóstico , Pulsoterapia , Medição de Risco , Índice de Gravidade de DoençaAssuntos
Hipopituitarismo , Biomarcadores/análise , Demência/etiologia , Diagnóstico Diferencial , Diagnóstico por Imagem , Terapia de Reposição Hormonal , Humanos , Hipopituitarismo/diagnóstico , Hipopituitarismo/tratamento farmacológico , Hipopituitarismo/etiologia , Testes de Função Hipofisária/métodos , Hormônios Hipofisários/análise , PrognósticoRESUMO
Thymic carcinoid in multiple endocrine neoplasia type 1 (MEN 1) is previously reported as a non-ACTH producing tumor. The present case is a 39-year-old man with mortal outcome from thymic carcinoid and Cushing's syndrome with high plasma ACTH. The symptom was first observed at age 29 and was relieved after extended thymectomy, with reduction of ACTH level. The tumor was positive for ACTH, Grimelius silver staining and Chromogranin A. The finding of primary hyperparathyroidism, pituitary adenoma, and a novel germline nonsense mutation (W423X) established the diagnosis of MEN 1. Cushing's syndrome due to ACTH producing thymic carcinoid should be also considered as one phenotype of the MEN 1 spectrum.
Assuntos
Síndrome de ACTH Ectópico/etiologia , Tumor Carcinoide/complicações , Síndrome de Cushing/etiologia , Neoplasia Endócrina Múltipla Tipo 1/diagnóstico , Neoplasias do Timo/complicações , Síndrome de ACTH Ectópico/sangue , Hormônio Adrenocorticotrópico/sangue , Adulto , Antineoplásicos Hormonais/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Tumor Carcinoide/sangue , Tumor Carcinoide/patologia , Tumor Carcinoide/terapia , Terapia Combinada , Síndrome de Cushing/sangue , Evolução Fatal , Mutação em Linhagem Germinativa , Humanos , Masculino , Neoplasia Endócrina Múltipla Tipo 1/sangue , Neoplasia Endócrina Múltipla Tipo 1/genética , Neoplasia Endócrina Múltipla Tipo 1/terapia , Octreotida/uso terapêutico , Radioterapia Adjuvante , Timectomia , Neoplasias do Timo/sangue , Neoplasias do Timo/patologia , Neoplasias do Timo/terapiaRESUMO
OBJECTIVE: To identify the distribution of thyrostimulin, a heterodimer of glycoprotein hormone subunits (A2 and B5) by immunohistochemistry in the rat tissues using specific antipeptide anti-serum which we recently produced. METHOD: Anti-thyrostimulin antibody was raised in New Zealand white rabbits immunized with a conjugate of synthetic A2 or B5 with bovine serum albumin. Immunohistochemical analysis was performed by avidin-biotin complex method. RESULTS: Thyrostimulin immunoreactivity was visualized in the anterior pituitary, central nervous system, adrenal gland, stomach, duodenum, pancreas and testis. When using antiserum pre-incubated with synthetic peptides or rat pituitary homogenate which contains thyrostimulin peptide, no significant stain of the pituitary was detected. CONCLUSION: These findings suggest that thyrostimulin is widely distributed and that the method used is valuable in studying the distribution of thyrostimulin in rats.
Assuntos
Glicoproteínas/metabolismo , Animais , Avidina , Biotina , Soros Imunes , Imuno-Histoquímica/métodos , Imuno-Histoquímica/normas , Masculino , Ratos , Ratos Wistar , Distribuição TecidualRESUMO
OBJECTIVE: To develop radioimmunoassay for aquaporin-9 (AQP9) and search for its presence in certain rat tissues. METHODS: Anti-AQP9 antiserum has been raised in New Zealand white rabbits immunized with a conjugate of synthetic AQP9 with bovine serum albumin. Radioiodination of AQP9 was performed by chloramin T method followed by purification of radioiodinated material on Sephadex G-25 column. RESULTS: The obtained antibody did not crossreact with other aquaporins, hypothalamic hormones, pituitary hormones, neuropeptides or gut hormones. The assay was performed with a double antibody system. AQP9 was extracted from the tissues with acid acetone. The dilution curve of acid acetone extracts of rat liver in the radioimmunoassay system was parallel to the standard curve. The recovery of tissue AQP9 was about 90%, and the intra-assay and inter-assay variations were 4.8% and 7.9%, respectively. AQP9 was found in the liver, testis and brain. CONCLUSION: These data suggest that this assay system is suitable for the estimation of AQP9 in the tissues.